Are Puberty Blockers Safe? A Sourced Guide for Families

TransHealthHub

Sep 10

6 min read

Key Takeaways

Puberty blockers (also called puberty-pausing medication) are regarded as safe when prescribed and monitored by a qualified clinician, according to the Endocrine Society and other major U.S. medical organizations.
You may see this care described as puberty blockers, hormone-suppressing medication, or puberty-pausing medication. This guide uses "puberty-pausing medication" for clarity, and the terms describe the same treatment.
Short-term physical effects are usually mild. The effects that get the most attention, bone density and fertility, are tracked with scheduled testing rather than left to chance.
The Cass Review and a 2025 U.S. Department of Health and Human Services report rated parts of the underlying evidence as low certainty. A low-certainty rating means more long-term research is needed, not that harm has been demonstrated.
A large 2026 U.S. study of more than 41,000 transgender youth found this medication was associated with lower odds of a mood disorder or suicidal thoughts diagnosis, though the study's authors caution this shows an association, not a proven cause.

The short answer

Puberty-pausing medication is regarded as safe, when prescribed and monitored by a qualified clinician, by the American Medical Association, American Academy of Pediatrics, American Psychological Association, and Endocrine Society. Its short-term effects are usually mild, and the longer-term effects that clinicians watch most closely, mainly bone density and fertility, are tracked through regular testing rather than guesswork. At TransHealthHub, we think families deserve to see both halves of the safety picture: what the evidence supports and where real questions remain open.

Puberty blockers have been used since the 1980s to pause early puberty in children generally, and the same medication is used, with the same monitoring approach, for transgender adolescents.

What "safe" actually means for this medication

In medicine, "safe" rarely means risk-free. It means a treatment's benefits, for a specific person and situation, outweigh its monitored risks. The Endocrine Society's position statement on transgender health describes puberty suppression as "effective, relatively safe (when appropriately monitored), and... established as the standard of care" for eligible transgender youth. That phrase, "when appropriately monitored," is doing real work: it is why regular bloodwork, bone scans, and growth checks are part of standard care rather than an optional extra.

The Mayo Clinic lists the effects reported most often as injection-site swelling, weight gain, hot flashes, headaches, and mood changes, most of which resolve once a young person adjusts to treatment. TransHealthHub's page on puberty blocker side effects covers what is commonly reported day-to-day in more depth.

What the longer-term evidence shows, and what's still being studied

The physical effects that require the most monitoring are bone density and fertility, since both are tied to processes puberty itself normally drives. A 2020 study of 63 early-pubertal transgender youth at four U.S. academic pediatric gender centers found that a meaningful share already had lower bone density scores before starting treatment at all, with at least one low score in 30 percent of youth designated male at birth (10 of 33) and 13 percent of youth designated female at birth (4 of 30). Because those scores were measured before treatment began, they cannot be attributed to the medication itself. TransHealthHub's page on puberty blockers and bone density walks through what happens to those scores during and after treatment in detail.

Fertility depends heavily on when in puberty a young person starts treatment and how long they continue it, which is why the Endocrine Society's clinical practice guideline instructs clinicians to counsel every young person on fertility preservation options before starting. Our page on long-term effects of puberty blockers covers what multi-year data shows across bone density, fertility, and growth together.

Some of the loudest disagreement about this medication is really a disagreement about how much high-quality, long-term research exists, not about whether harm has been shown. The Cass Review, a UK government-commissioned review, and a 2025 U.S. Department of Health and Human Services report both rated the certainty of parts of the pediatric evidence base as low. As KFF's neutral summary of the HHS report puts it, the underlying research shows "the quality of evidence on the effects of any intervention is low, and evidence on harms is sparse." A low-certainty rating is a statement about the strength of the available research, not a finding that this medication causes harm, and it sits alongside, not instead of, the position taken by the country's major medical associations below.

What U.S. medical organizations say

The American Medical Association, American Academy of Pediatrics, American Psychological Association, and Endocrine Society all continue to regard this type of care, prescribed and monitored by a qualified clinician, as medically necessary and evidence-based for adolescents with persistent gender dysphoria. In 2023, the AMA's House of Delegates strengthened its policy after noting that more than 2,000 scientific studies have examined aspects of this type of care since 1975, including more than 260 cited in the Endocrine Society's own clinical practice guideline.

Mental health data points in a similar direction. A 2026 study in JAMA Network Open examined insurance claims for more than 231,000 U.S. youth, including over 41,000 transgender youth, and found this medication was associated with lower odds of a mood disorder or suicidal thoughts diagnosis, though the study's authors were careful to note that claims data show an association, not proof of cause and effect. That caution matters and should be preserved whenever this finding is cited. None of this means every question is settled. Long-term data, especially multi-year bone density and psychological outcomes reaching into adulthood, remains an active area of research, and TransHealthHub tries to say so plainly rather than overstate what is known in either direction.

What's tracked, and what the evidence shows so far

Area of safety	What the evidence shows so far	How it's monitored
Short-term physical effects	Usually mild: swelling, hot flashes, headaches, mood changes	Reviewed at routine follow-up visits
Bone density	Some youth show lower scores even before treatment begins; scores are actively tracked and often improve once hormone therapy starts	Yearly bone density and bone age tests, plus calcium and vitamin D as needed
Fertility	Effects depend on timing and duration of treatment	Fertility preservation counseling before treatment starts
Growth	Pubertal growth spurt is paused along with other changes	Height checked every few months
Mental health	Associated with lower odds of mood disorder and suicidal thoughts diagnoses in one large U.S. study	Ongoing clinical follow-up and further research
Certainty of the evidence	Rated low by some reviews for long-term outcomes; this reflects the amount of research available, not demonstrated harm	Paired with ongoing medical-society consensus and new studies as they publish

Frequently asked questions

Are puberty blockers safe long-term? Short-term effects are usually mild. Longer-term, bone density and fertility are the effects clinicians track most closely, and current evidence shows bone density often improves once hormone therapy begins, though some studies say more multi-year data is still needed to be fully confident about every detail.

What do doctors monitor to keep puberty-pausing medication safe? Standard care includes regular bloodwork, yearly bone density and bone age tests, growth checks every few months, and fertility preservation counseling before starting, all reviewed at routine follow-up visits.

Why do some reports say the evidence on this medication is uncertain? Reviews like the Cass Review and a 2025 HHS report rated parts of the long-term evidence base as low certainty, meaning more high-quality research is needed. That is different from finding that the medication causes harm, and major U.S. medical associations still regard it as safe when appropriately monitored.